7 October 2024 India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative.
Political and health leaders have signed and adopted the Nagasaki Outcomes Statement, calling for accelerated R&D, access, and delivery for neglected tropical diseases (NTDs). 4 July 2023
The Russian Ministry of Health has called on domestic drugmakers to accelerate efforts for the development and production of cheaper analogues of expensive drugs, particularly those that are used for the treatment of socially significant diseases, according to recent statements made by Sergey Glagolev, deputy head of the Ministry. 4 July 2023
For many years, Britain’s pharma largest company AstraZeneca has maintained a strong presence in China, and this approach looks set to pay off. 4 July 2023
Developing new drugs is a complex and expensive process with a high failure rate. In fact, only about one out of 250 preclinical compounds make it to FDA approval. With an average cost of $40,000 per patient in a phase three clinical trial, the financial impact of failure is staggering. 4 July 2023
A life-changing treatment to prevent blindness in premature babies is to be routinely available on England’s National Health Service (NHS), it was revealed today. 4 July 2023
German family-owned pharma major Boehringer Ingelheim today presented new late-breaking data from the EFFISAYIL trial showing that patients receiving the highest dose of spesolimab experienced significantly reduced generalized pustular psoriasis (GPP) flares by 84% over 48 weeks compared to placebo (hazard ratio 0.157; 95% confidence interval 0.05–0.54; p=0.0005). 4 July 2023
Japanese drugmaker Maruho has entered into an exclusive license agreement to develop and commercialize Alchemedicine's aldehyde dehydrogenase 2 (ALDH2) activator following Maruho's exercise of the option right included in the exclusive negotiation and evaluation agreement that had already been executed between the companies. 4 July 2023
Swiss generic drugmaker Dipharma today announced that its product Sapropterin Dipharma is now available in main European countries including in Switzerland. 3 July 2023
The general assembly of the International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use (ICH) has adopted a new topic focused on the harmonization of bioequivalence for modified-release products. 3 July 2023
With the block on biosimilar versions of AbbVie’s (NYSE: ABBV) mega blockbuster Humira (adalimumab) now removed in the USA, the weekend witnessed the launch of three copycat products in the American market. 3 July 2023
Shares of UK pharma major AstraZeneca fell 5.5% to £10,652 this morning, after it released new data from the TROPION-Lung01 Phase III trial of its TROP2-directed antibody drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd). 3 July 2023
Barcelona, Spain-based plasma-derived medicine specialist Grifols says it has now started marketing Xembify, its 20% subcutaneous immunoglobulin, in Spain. 3 July 2023
Genentech, the US biotech subsidiary of Swiss pharma giant Roche, plans to withdraw Gavreto (pralsetinib) from use in the USA for the treatment of a type of RET+ medullary thyroid cancer (MTC) as it was not feasible to pursue the drug for full approval, its partner Blueprint Medicines said on Friday. 3 July 2023
News coming out of Cure SMA meeting on new 36-month extension data from US biotech Scholar Rock’s Phase II TOPAZ clinical trial reinforces long-term substantial and sustained improvement of motor function in patients with non-ambulatory spinal muscular atrophy (SMA) treated with apitegromab. 3 July 2023
The US Department of Health and Human Services (HHS) on Friday announced actions to lower health care costs and implement President Biden’s lower cost prescription drug law – the Inflation Reduction Act (IRA) – which is already saving covered seniors and people with disabilities hundreds of dollars annually. 3 July 2023
UK-based AviadoBio, a LifeArc Ventures portfolio company, and Astellas Pharma today announced an exclusive option and license agreement for AVB-101. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Israel-based Teva Pharmaceutical Industries today announced that the US Food and Drug Administration (FDA) has accepted, and the European Medicines Agency (EMA) has validated, applications for TVB-009P, a biosimilar candidate to Prolia (denosumab). 8 October 2024
UK-based Mestag Therapeutics has entered into a license and collaboration agreement with Merck & Co to explore new therapeutic options for inflammatory diseases. 8 October 2024
With its recent US Food and Drug Administration (FDA) approval, Eli Lilly’s Ebglyss (lebrikizumab) adds a new competitor to the atopic dermatitis (AD) market. 8 October 2024
US antivirals specialist Gilead Sciences has released additional data from its pivotal Phase III PURPOSE 2 trial providing an overview of the efficacy and safety of twice-yearly lenacapavir. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Novo Nordisk has reached a settlement with Mylan Pharmaceuticals, now part of Viatris, putting an end to a US patent lawsuit over blockbuster diabetes treatment Ozempic (semaglutide). 8 October 2024
UK-based ViiV Healthcare, the specialist HIV company majority-owned by GSK (LSE: GSK), with Pfizer and Shionogi as shareholders, has announced a milestone in its efforts to achieve widespread international access to its therapies. 7 October 2024
Texas Attorney General Ken Paxton has filed a lawsuit against major pharmaceutical companies, including Eli Lilly (NYSE: LLY), alleging a conspiracy to artificially inflate the prices of insulin by up to 1,000%. 7 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Orchard Therapeutics has signed an exclusive distribution agreement with Turkish drugmaker Er-Kim, for the gene therapy Libmeldy (atidarsagene autotemcel). 7 October 2024
Cambridge, USA-based biotech Judo Bio has announced the company’s launch and $100 million in initial financing, including seed financing and Series A. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
ABL Bio Corp on Friday revealed that it has entered into a clinical trial collaboration and supply agreement with MSD (the ex-US/Canada trading name of Merck & Co. 7 October 2024